Thymosin Alpha-1 (Thymalfasin)
Immune · By Preptide Pro editorial team · Last updated
Thymosin Alpha-1 (Thymalfasin) is a immune peptide, and it is not FDA-approved. A 28-amino-acid immune-modulating peptide. It is approved in some countries outside the US and has been studied for hepatitis and as a vaccine adjuvant.
Not FDA-approvedChemistry (PubChem)
| PubChem CID | 16130571 |
|---|---|
| CAS number | 62304-98-7 |
| Molecular formula | C129H215N33O55 |
| Molecular weight | 3108.3 g/mol |
| Other names | Thymalfasin, Thymosin alpha 1, Thymosin alpha1, Zadaxin, alpha1-Thymosin, Thymosin alpha1 (human), thymalfasine, timalfasina |
Is Thymosin Alpha-1 (Thymalfasin) FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on Thymosin Alpha-1 (Thymalfasin)?
PubMed lists 872 records for “"thymosin alpha 1" OR thymalfasin”, of which 93 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Thymosin α1-induced secretion of the IL-15/RA complex by THP-1-derived dendritic cells restrains HIV latency in vitro. | Virulence | 2026 Dec |
| A novel porcine interleukin-2-interferon-α-thymosin α1 tripartite fusion protein confers antiviral activity against pseudorabies virus. | Vet Microbiol | 2026 Nov |
| Thymosin α-1 in cancer therapy: Immunomodulatory mechanisms, clinical applications, and translational perspectives. | Eur J Pharmacol | 2026 Oct 28 |
| Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review. | Pharmaceuticals (Basel) | 2026 Sep 19 |
| Efficacy and safety of thymosin α1 combined with chemotherapy for gastric cancer: a systematic review and meta-analysis of randomized controlled trials. | Front Immunol | 2026 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.